These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 35038723)
1. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Cornblath DR; van Doorn PA; Hartung HP; Merkies ISJ; Katzberg HD; Hinterberger D; Clodi E; Brain; 2022 Apr; 145(3):887-896. PubMed ID: 35038723 [TBL] [Abstract][Full Text] [Related]
2. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842 [TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study. Cornblath DR; van Doorn PA; Hartung HP; Merkies ISJ; Katzberg HD; Hinterberger D; Clodi E; Drug Saf; 2023 Sep; 46(9):835-845. PubMed ID: 37378806 [TBL] [Abstract][Full Text] [Related]
4. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F; Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS; Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. Kuwabara S; Mori M; Misawa S; Suzuki M; Nishiyama K; Mutoh T; Doi S; Kokubun N; Kamijo M; Yoshikawa H; Abe K; Nishida Y; Okada K; Sekiguchi K; Sakamoto K; Kusunoki S; Sobue G; Kaji R; J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):832-838. PubMed ID: 28768822 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). Léger JM; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Mielke O; Tackenberg B; Shebl A; Bauhofer A; Zenker O; Merkies IS; J Peripher Nerv Syst; 2013 Jun; 18(2):130-40. PubMed ID: 23781960 [TBL] [Abstract][Full Text] [Related]
9. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN; J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523 [TBL] [Abstract][Full Text] [Related]